Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc., trading under the ticker LGST, is a clinical-stage biopharmaceutical company focused on off-the-shelf T-cell immunotherapies targeting infectious diseases and oncology indications, placing it within the healthcare and life sciences sector. The company reached the public markets through a SPAC merger, a common route for clinical-stage biotechnology names during the 2021–2022 blank-check wave. In August 2022, Tevogen Bio filed a Form 10-Q with the SEC, reflecting its status as a reporting public company following completion of its de-SPAC transaction. The quarterly filing covers the company's operations and financial position as it advances its proprietary T-cell platform. For full filing history, sponsor details, and deal timelines on Tevogen Bio and the broader SPAC market, sign up for complete data access at SpacDesk.